Search results
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
Our Products. Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. With a presence in approximately 100 countries, we are proud to have reached millions of people with our products.
Live. Win. Thrive. We dare to ask questions that lead to lifesaving treatments. Join us in pushing the boundaries of biotechnology in a career at Amgen.
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 [5] (8.5% of total city employment) [6] and included ...
AMAT Applied Materials, Inc. 237.65. +3.34%. Find the latest Amgen Inc. (AMGN) stock quote, history, news and other vital information to help you with your stock trading and investing.
Amgen is a pioneer in the science of using living cells to make biologic medicines. We helped invent the processes and tools that built the global biotech industry—turning it into a leading source of therapies for patients.
Jan 31, 2023 · THOUSAND OAKS, Calif., Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira ®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016. 2,3.
